Tom 8, Nr 6 (2022)
Artykuł przeglądowy
Opublikowany online: 2021-08-16
Wyświetlenia strony
2038
Wyświetlenia/pobrania artykułu
222
Niedokrwistość u chorych na raka płuca — diagnostyka, różnicowanie i leczenie
Onkol Prakt Klin Edu 2022;8(6):458-464.
Streszczenie
Charakterystyka niedokrwistości — w tym rozpowszechnienie, patomechanizm oraz metody i wyniki leczenia — u chorych z rozpoznanym rakiem płuca wydaje się istotnie nie odbiegać od ogólnej populacji chorych na nowotwory złośliwe. Niedokrwistość u chorych onkologicznych może wynikać z szerokiego spektrum przyczyn, które za każdym razem należy określić indywidualnie, tak aby wprowadzone leczenie było możliwie jak najbardziej celowane. Analizując możliwą etiologię, trzeba również wziąć pod uwagę tak zwaną niedokrwistość towarzyszącą nowotworowi, w tym indukowaną przez chemioterapię. W zakresie leczenia niedokrwistości u chorych onkologicznych istnieje potrzeba prowadzenia dalszych badań nad długofalową skutecznością i bezpieczeństwem różnych form terapii.
Słowa kluczowe: niedokrwistośćrak płucaerytropoetynażelazo
Referencje
- World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity (No. WHO/NMH/NHD/MNM/11.1). 2011.
- Wouters HJ, van der Klauw MM, de Witte T, et al. Association of anemia with health-related quality of life and survival: a large population-based cohort study. Haematologica. 2019; 104(3): 468–476.
- Carnio S, Di Stefano RF, Novello S. Fatigue in lung cancer patients: symptom burden and management of challenges. Lung Cancer (Auckl). 2016; 7: 73–82.
- Wojciechowska U, Didkowska J, Michałek I, et al. Nowotwory złośliwe w Polsce w 2018 roku. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy. 2020. http://onkologia.org.pl/raporty/ (04.06.2021).
- Kang HS, Shin AhY, Yeo CD, et al. Clinical significance of anemia as a prognostic factor in non-small cell lung cancer carcinoma with activating epidermal growth factor receptor mutations. J Thorac Dis. 2020; 12(5): 1895–1902.
- J B, J J. Callahan, R. C. . Anemia in older adults. American family physician. 2018; 98(7): 437–442.
- Stauder R, Valent P, Theurl I. Anemia at older age: etiologies, clinical implications, and management. Blood. 2018; 131(5): 505–514.
- Kenar G, Köksoy EB, Ürün Y, et al. Prevalence, etiology and risk factors of anemia in patients with newly diagnosed cancer. Support Care Cancer. 2020; 28(11): 5235–5242.
- Radziwon P, Krzakowski M, Kalinka E, et al. Anemia in cancer patients — Expert Group recommendations. Revision 2020. Oncol ClinPract 2020. 2020; 16(5): 261–269.
- Majdan A. Erytropoetyna w leczeniu niedokrwistości w przebiegu nowotworów złośliwych–czy ewentualne korzyści przewyższają ryzyko? Oncology. 2017; 3(41): 053–061.
- Gilreath JA, Stenehjem DD, Rodgers GM. Diagnosis and treatment of cancer-related anemia. Am J Hematol. 2014; 89(2): 203–212.
- Madeddu C, Gramignano G, Astara G, et al. Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach. Front Physiol. 2018; 9: 1294.
- Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res. 1998; 18(8): 555–559.
- Means RT. Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cells. 1995; 13(1): 32–37.
- Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004; 40(15): 2293–2306.
- Kosmidis P, Krzakowski M. ECAS Investigators. Anemia profiles in patients with lung cancer: what have we learned from the European Cancer Anaemia Survey (ECAS)? Lung Cancer. 2005; 50(3): 401–412.
- Wojtukiewicz MZ, Sierko E, Rybaltowski M, et al. The Polish Cancer Anemia Survey (POLCAS): a retrospective multicenter study of 999 cases. Int J Hematol. 2009; 89(3): 276–284.
- Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999; 91(19): 1616–1634.
- Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004; 40(15): 2293–2306.
- Hébert PC, McDonald BJ, Tinmouth A. Clinical consequences of anemia and red cell transfusion in the critically ill. Critical care clinics. 2004; 20(2): 225–235.
- McIntyre L, Fergusson D, Hutchison J, et al. Effect of a Liberal Versus Restrictive Transfusion Strategy on Mortality in Patients With Moderate to Severe Head Injury. Neurocritical Care. 2006; 5(1): 4–9.
- Caram-Deelder C, Kreuger AL, Evers D, et al. Association of Blood Transfusion From Female Donors With and Without a History of Pregnancy With Mortality Among Male and Female Transfusion Recipients. JAMA. 2017; 318(15): 1471–1478.
- Ydy LRA, Slhessarenko N, de Aguilar-Nascimento JE. Effect of perioperative allogeneic red blood cell transfusion on the immune-inflammatory response after colorectal cancer resection. World journal of surgery. 2007; 31(10): 2044–2051.
- Chau JK, Harris JR, Seikaly HR. Transfusion as a predictor of recurrence and survival in head and neck cancer surgery patients. Journal of Otolaryngology--Head & Neck Surgery. 2010; 39(5).
- Panagopoulos ND, Karakantza M, Koletsis E, et al. Influence of blood transfusions and preoperative anemia on long-term survival in patients operated for non-small cell lung cancer. Lung Cancer. 2008; 62(2): 273–280.
- Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006(1): CD005033.
- Schiergens TS, Rentsch M, Kasparek MS, et al. Impact of perioperative allogeneic red blood cell transfusion on recurrence and overall survival after resection of colorectal liver metastases. Diseases of the Colon & Rectum. 2015; 58(1): 74–82.
- Kooby DA, Stockman J, Ben-Porat L, et al. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Annals of surgery. 2003; 237(6): 860.
- Castillo JJ, Dalia S, Pascual SK. Association between red blood cell transfusions and development of non-Hodgkin lymphoma: a meta-analysis of observational studies. Blood, The Journal of the American Society of Hematology. 2010; 116(16): 2897–2907.
- Radziwon P, Wojtukiewicz MZ. Bezpieczne i skuteczne stosowanie składników krwi w onkologii. In: Wojtukiewicz MZ, Deptała A. ed. Problemy hematologiczne u chorych na nowotwory. Termedia Wydawnictwa Medyczne, Poznań 2014: 449–475.
- Aapro M, Beguin Y, Bokemeyer C, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Annals of Oncology. 2018; 29: 96–110.
- Abdel-Razeq H, Hashem H. Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia. Crit Rev Oncol Hematol. 2020; 145: 102837.
- Szenajch JM, Synowiec AE. [Erythropoietin and drug resistance in breast and ovarian cancers]. Ginekol Pol. 2016; 87(4): 300–304.
- FDA. Postmarket Drug Safety Information for Patients and Providers > Information on Erythropoiesis-Stimulating Agents (ESA) Epoetin alfa (marketed as Procrit, Epogen), Darbepoetin alfa (marketed as Aranesp) 31.03.2017.
- Vansteenkiste J, Glaspy J, Henry D, et al. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. Lung Cancer. 2012; 76(3): 478–485.
- Pirker R, Hedenus M, Vansteenkiste J, et al. Effectiveness of Darbepoetin Alfa for Chemotherapy-induced Anemia When Initiated at Hemoglobin ≤10 g/dL. Clin Ther. 2016; 38(1): 122–135.e6.
- Mafodda A, Giuffrida D, Prestifilippo A, et al. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study. Support Care Cancer. 2017; 25(9): 2779–2786.
- Bohlius J, Bohlke K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv. 2019; 3(8): 1197–1210.
- Hameed EN, Hadi Al Tukmagi HF, Allami HC. Melatonin Improves Erythropoietin Hyporesponsiveness via Suppression of Inflammation. Rev Recent Clin Trials. 2019; 14(3): 203–208.
- Kam PMH, Chu CWH, Chan EMY, et al. Use of intravenous iron therapy in colorectal cancer patient with iron deficiency anemia: a propensity-score matched study. Int J Colorectal Dis. 2020; 35(3): 521–527.
- Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015; 90(1): 12–23.
- European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron‐containing medicines. 2013.
